Shopping Cart

Your shopping cart is currently empty

Prasugrel

Name: Prasugrel
Brand: TargetMol
SKU: T0230
Price: 37 USD
Availability: InStock
Rating: 5 (10 reviews)

Copy Product Info

🥰Excellent

Catalog No. T0230Cas No. 150322-43-3

Alias PCR 4099, LY640315, CS-747

Prasugrel (CS-747) is a piperazine derivative and PLATELET AGGREGATION INHIBITOR that is used to prevent THROMBOSIS in patients with ACUTE CORONARY SYNDROME; UNSTABLE ANGINA and MYOCARDIAL INFARCTION, as well as in those undergoing PERCUTANEOUS CORONARY INTERVENTIONS.

Prasugrel

Copy Product Info

🥰Excellent

Purity: 99.82%

Catalog No. T0230Alias PCR 4099, LY640315, CS-747Cas No. 150322-43-3

Pack Size	Price	USA Warehouse	Global Warehouse
50 mg	$37	In Stock	In Stock
100 mg	$52	In Stock	In Stock
500 mg	$129	In Stock	In Stock
1 g	$193	In Stock	In Stock
1 mL x 10 mM (in DMSO)	$50	In Stock	In Stock

Add to Cart

Add to Quotation

In Stock Estimated shipping dateUSA Warehouse[1-2 days] Global Warehouse[5-7 days]

All TargetMol products are for research purposes only and cannot be used for human consumption. We do not provide products or services to individuals. Please comply with the intended use and do not use TargetMol products for any other purpose.

Questions

Batch Information

Select Batch

Purity:99.82%

Appearance:Solid

Color:White to Yellow

Resource Download

COA HNMR LCMS

Product Introduction

Prasugrel AI Summary

Prasugrel exhibits a broad range of bioactivities across various biological systems. Its antiplatelet activity is demonstrated in both Wistar rats and Balb/c mice through the inhibition of ADP-induced platelet aggregation, measured at different dosages and time points, with observed activity levels such as 32.1% inhibition in rats at 3 mg/kg orally and prolongation of bleeding time in mice at 30 mg/kg intravenously. In terms of antiviral properties, Prasugrel shows variable activity against SARS-CoV-2, Ebola virus, and other pathogens. It inhibits the proliferation of Plasmodium falciparum strains at concentrations ranging from 6.7 nM to 23,694.5 nM. For SARS-CoV-2, it exhibits inhibition of cytotoxicity in different cell lines, including Caco-2 and Vero E6 cells, with varying efficacy. Additionally, it shows a hit score of 0.2148 in HRCE cells for the SARS-CoV-2 USA-WA1/2020 strain. In the context of drug metabolism, Prasugrel inhibits CYP2B6 in humans, affecting systemic exposure of metabolites like hydroxybupropion. Its half-life in rat intestinal microsomes is 0.01667 hours at a concentration of 1 µM, suggesting limited stability. The compound also actively participates in metabolic pathways in beagle dogs, forming specific metabolites such as R-95913 and R-138727. Prasugrel shows an inhibitory effect on HDAC6 enzymes and P2Y12 with IC50 values of 1800.0 nM. It demonstrates moderate inhibition on human ABCB11 at an AC50 value of 3500.0 nM and shows agonistic activity towards human OPRM1, ADORA3, and others with relatively higher AC50 values. Its lipophilicity is indicated by a logP value of 3.42. Additionally, it inhibits the cell viability in SARS-CoV-2 infected Vero E6 cells, although with a low inhibition index. Overall, Prasugrel is a multi-faceted agent with significant antiplatelet, antiviral, and metabolic activities, alongside moderate effects on various enzymes and receptors in different biological systems..

Note: Summary generated by AI. Data source: ChEMBL

Bioactivity

Description	Prasugrel (CS-747) is a piperazine derivative and PLATELET AGGREGATION INHIBITOR that is used to prevent THROMBOSIS in patients with ACUTE CORONARY SYNDROME; UNSTABLE ANGINA and MYOCARDIAL INFARCTION, as well as in those undergoing PERCUTANEOUS CORONARY INTERVENTIONS.
Targets&IC50	Platelet:1.8 μM
In vitro	Prasugrel has a faster, higher and more reliable platelet aggregation inhibitory effect than clopidogrel and is metabolized in vivo to an active metabolite with selective P2Y(12) antagonistic activity.
In vivo	Prasugrel has a faster, higher and more reliable platelet aggregation inhibitory effect than clopidogrel and is metabolized in vivo to an active metabolite with selective P2Y(12) antagonistic activity.
Synonyms	PCR 4099, LY640315, CS-747

Chemical Properties

Molecular Weight	373.44
Formula	C₂₀H₂₀FNO₃S
Cas No.	150322-43-3
Smiles	C(C(=O)C1CC1)(N2CC3=C(CC2)SC(OC(C)=O)=C3)C4=C(F)C=CC=C4
Relative Density.	1.347

Storage & Solubility Information

Storage

Powder: -20°C for 3 years | In solvent: -80°C for 1 year | Shipping with blue ice/Shipping at ambient temperature.

Solubility Information

DMSO: 45 mg/mL (120.5 mM), Sonication is recommended.

In Vivo Formulation

10% DMSO+40% PEG300+5% Tween 80+45% Saline: 2 mg/mL (5.36 mM), Sonication is recommended.

Please add the solvents sequentially, clarifying the solution as much as possible before adding the next one. Dissolve by heating and/or sonication if necessary. Working solution is recommended to be prepared and used immediately. The formulation provided above is for reference purposes only. In vivo formulations may vary and should be modified based on specific experimental conditions.

Solution Preparation Table

DMSO

	1mg	5mg	10mg	50mg
1 mM	2.6778 mL	13.3890 mL	26.7781 mL	133.8903 mL
5 mM	0.5356 mL	2.6778 mL	5.3556 mL	26.7781 mL
10 mM	0.2678 mL	1.3389 mL	2.6778 mL	13.3890 mL
20 mM	0.1339 mL	0.6695 mL	1.3389 mL	6.6945 mL
50 mM	0.0536 mL	0.2678 mL	0.5356 mL	2.6778 mL
100 mM	0.0268 mL	0.1339 mL	0.2678 mL	1.3389 mL

Calculator

Molarity Calculator
Dilution Calculator
Reconstitution Calculator
Molecular Weight Calculator

In Vivo Formulation Calculator (Clear solution)

Please enter your animal experiment information in the following box and click Calculate to obtain the stock solution preparation method and in vivo formula preparation method:

For example, if the intended dosage is 10 mg/kg for animals weighing 20 g , with a dosing volume of 100 μL per animal, TargetMol | Animal experiments

and a total of 10 animals are to be administered, using a formulation of TargetMol | reagent

10% DMSO+ 40% PEG300+ 5% Tween 80+ 45% Saline/PBS/ddH₂O , the resulting working solution concentration would be 2 mg/mL.

Stock Solution Preparation:

Dissolve 2 mg of the compound in 100 μL DMSO TargetMol | reagent to obtain a stock solution at a concentration of 20 mg/mL . If the required concentration exceeds the compound's known solubility, please contact us for technical support before proceeding.

Preparation of the In Vivo Formulation:

1) Add 100 μL of the DMSO TargetMol | reagent stock solution to 400 μL PEG300 and mix thoroughly until the solution becomes clear.

2) Add 50 μL Tween 80 and mix well until fully clarified.

3) Add 450 μL Saline,PBS or ddH₂O TargetMol | reagent and mix thoroughly until a homogeneous solution is obtained.

This example is provided solely to demonstrate the use of the In Vivo Formulation Calculator and does not constitute a recommended formulation for any specific compound. Please select an appropriate dissolution and formulation strategy based on your experimental model and route of administration.

All co-solvents required for this protocol, includingDMSO, PEG300/PEG400, Tween 80, SBE-β-CD, and Corn oil, are available for purchase on the TargetMol website.

Dose Conversion

You can also refer to dose conversion for different animals. More Dose Conversion

Tech Support

Please see Inhibitor Handling Instructions for more frequently ask questions. Topics include: how to prepare stock solutions, how to store products, and cautions on cell-based assays & animal experiments, etc